Get the Stockscreener App
0.6695
1.22%
0.0081
After Hours:
29.72
29.05
+4,339%
Relmada Therapeutics Inc stock is traded at $0.6695, with a volume of 328.94K.
It is up +1.22% in the last 24 hours and up +3.53% over the past month.
Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its key product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.
See More
Previous Close:
$0.6614
Open:
$0.652
24h Volume:
328.94K
Relative Volume:
1.11
Market Cap:
$22.22M
Revenue:
-
Net Income/Loss:
$-98.79M
P/E Ratio:
-0.2047
EPS:
-3.27
Net Cash Flow:
$-51.66M
1W Performance:
+9.31%
1M Performance:
+3.53%
6M Performance:
+142.66%
1Y Performance:
-75.39%
1-Day Range:
$0.612
$0.6912
1-Week Range:
$0.59
$0.6912
52-Week Range:
$0.2404
$3.98
Relmada Therapeutics Inc Stock (RLMD) Company Profile
Name
Relmada Therapeutics Inc
Sector
Industry
Phone
646 876 3459
Address
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
Compare RLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
| 3.03 | 0 | 0 | 0 | 0 | 0.00 | |
MOBBW
Mobilicom Limited Warrants
|
1.585 | 1.86B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.42 | 372.90M | 0 | 0 | 0 | 0.00 |
|
SHMD
Schmid Group N V
|
2.64 | 118.42M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
0.47 | 360.07M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
DAVEW
Dave Inc
|
1.25 | 0 | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-05-24 | Downgrade | Mizuho | Outperform → Neutral |
| Sep-17-24 | Upgrade | Jefferies | Hold → Buy |
| Jun-05-24 | Downgrade | Goldman | Neutral → Sell |
| Oct-14-22 | Downgrade | Goldman | Buy → Neutral |
| Oct-14-22 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-14-22 | Downgrade | Truist | Buy → Hold |
| Oct-13-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Nov-18-21 | Initiated | Mizuho | Buy |
| May-20-21 | Resumed | Goldman | Buy |
| Oct-28-20 | Downgrade | Goldman | Buy → Neutral |
| Jul-14-20 | Initiated | Oppenheimer | Outperform |
| May-04-20 | Initiated | SunTrust | Buy |
| Apr-21-20 | Initiated | Goldman | Buy |
| Jan-27-20 | Initiated | Jefferies | Buy |
| Jan-10-20 | Initiated | SVB Leerink | Outperform |
| Dec-16-19 | Initiated | Guggenheim | Buy |
View All
Relmada Therapeutics Inc Stock (RLMD) Latest News
What MACD signals say about Relmada Therapeutics Inc.2025 Top Decliners & Verified Swing Trading Watchlist - Newser
Is it too late to sell Relmada Therapeutics Inc.Options Play & Weekly Return Optimization Plans - Newser
Price momentum metrics for Relmada Therapeutics Inc. explainedJuly 2025 PreEarnings & Precise Buy Zone Identification - Newser
Is Relmada Therapeutics Inc. a candidate for recovery playJuly 2025 Trends & AI Based Buy/Sell Signal Reports - Newser
Is it time to cut losses on Relmada Therapeutics Inc.July 2025 Breakouts & AI Optimized Trade Strategies - Newser
Advanced analytics toolkit walkthrough for Relmada Therapeutics Inc.July 2025 Institutional & Growth Focused Entry Reports - Newser
Relmada Therapeutics Inc. stock trend outlook and recovery path2025 Momentum Check & Expert Curated Trade Setup Alerts - Newser
Best data tools to analyze Relmada Therapeutics Inc. stockGap Up & Fast Entry Momentum Trade Alerts - Newser
Statistical indicators supporting Relmada Therapeutics Inc.’s strengthTrade Performance Summary & Growth Focused Stock Pick Reports - Newser
Analyzing Relmada Therapeutics Inc. with multi timeframe chartsWeekly Gains Report & Smart Money Movement Tracker - Newser
Market reaction to Relmada Therapeutics Inc.’s recent news2025 Bull vs Bear & Stock Portfolio Risk Control - Newser
Is a relief rally coming for Relmada Therapeutics Inc. holdersQuarterly Portfolio Report & Long-Term Investment Growth Plans - Newser
Chartists See Breakout Potential in Relmada Therapeutics Inc. getLinesFromResByArray error: size == 0 - kangso.co.kr
Using AI based signals to follow Relmada Therapeutics Inc.July 2025 Patterns & Intraday High Probability Setup Alerts - Newser
How to integrate Relmada Therapeutics Inc. into portfolio analysis toolsWeekly Trade Report & Verified Technical Trade Signals - Newser
What data driven models say about Relmada Therapeutics Inc.’s futureQuarterly Performance Summary & Technical Buy Zone Confirmation - Newser
Should you wait for a breakout in Relmada Therapeutics Inc.July 2025 Reactions & Accurate Buy Signal Alerts - Newser
Tools to assess Relmada Therapeutics Inc.’s risk profileJuly 2025 Opening Moves & Intraday High Probability Alerts - Newser
Evaluating Relmada Therapeutics Inc. with trendline analysisMarket Sentiment Summary & Risk Adjusted Buy/Sell Alerts - Newser
What’s next for Relmada Therapeutics Inc. stock pricePortfolio Update Summary & Entry Point Strategy Guides - Newser
Relmada Therapeutics Inc. stock momentum explainedEarnings Risk Summary & Short-Term Trading Alerts - Newser
Is Relmada Therapeutics Inc.’s growth already priced inJuly 2025 Momentum & Low Drawdown Investment Ideas - sundaytimes.kr
Published on: 2025-08-23 21:25:05 - Newser
What is Relmada Therapeutics Inc. s revenue forecastWeekly Earnings Recap & Risk Managed Trade Strategies - theviewers.co.kr
Aug Catalysts: Can Relmada Therapeutics Inc. maintain its current growth rateEarnings Risk Report & Fast Gaining Stock Strategy Reports - theviewers.co.kr
Will Relmada Therapeutics Inc. benefit from macro trendsJuly 2025 Spike Watch & Precise Swing Trade Entry Alerts - Newser
Machine Learning Models Forecast Relmada Therapeutics Inc. UptickPortfolio Return Summary & Consistent Profit Trade Alerts - kangso.co.kr
Why Relmada Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Rallies & Daily Profit Maximizing Tips - beatles.ru
Recovery Setup Building in Relmada Therapeutics Inc. Experts SayQuarterly Market Review & Community Shared Stock Ideas - beatles.ru
When is the best time to exit Relmada Therapeutics Inc.Weekly Stock Summary & Daily Volume Surge Signals - Newser
Will Relmada Therapeutics Inc. price bounce be sustainable2025 Biggest Moves & Precise Buy Zone Identification - Newser
Relmada Therapeutics Inc Stock (RLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.98%
8.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):